HRD and HRR Testing
Homologous recombination repair (HRR) is a pathway cells use to repair certain types of DNA damage. Homologous recombination deficiency (HRD) describes impaired function of this pathway and may occur because of changes in BRCA1, BRCA2, or other related genes.
What Testing May Include
- Analysis of selected HRR-related genes in tumour tissue and, when appropriate, germline testing.
- Assessment of genomic-instability measures used by a validated HRD assay.
- Review of tumour type, prior results, and current treatment-related guidance.
Clinical Use
In selected cancers, HRR or HRD results may contribute to treatment planning or clinical-trial assessment. Eligibility criteria and interpretation depend on the tumour type, assay, treatment setting, and current guidelines.
Important Limitations
An HRR gene variant and an HRD result are not interchangeable. A negative result does not exclude every form of homologous-recombination deficiency. Tumour content, specimen quality, panel scope, and the assay’s validated threshold can affect interpretation.
Testing at Jaipur Molecular Lab
Contact our team to confirm the available assay, accepted specimen type, reportable genes or metrics, and the expected reporting timeline.
This information is for general education and does not replace medical advice. Test selection and interpretation should be discussed with the treating clinician and pathologist.